粪便免疫化学检测或多靶点粪便DNA检测阳性后结肠镜随访的障碍
该研究在学术健康系统内回顾性分析2016年1月至2018年6月间FIT或mt-sDNA阳性且年龄≥40岁的初级保健患者,发现mt-sDNA阳性者6个月内结肠镜完成率(71.5%)高于FIT阳性者(46.7%),且未随访者中提供者与系统障碍与患者障碍同样常见,提示需多层面干预。
要点
- mt-sDNA阳性者6个月内结肠镜完成率71.5%,高于FIT阳性者的46.7%。
- 未完成结肠镜者中,提供者相关障碍在FIT后占57.6%、mt-sDNA后占43.5%。
- 系统与患者障碍也常见,需多层面干预改善随访。
核心结论
- mt-sDNA阳性后结肠镜随访率高于FIT阳性,部分可能源于临床医生和/或患者的选择偏倚。
- 未随访者中提供者和系统因素与患者因素同样常见,需多层面干预。
研究设计与样本
- 回顾性分析学术健康系统内年龄≥40岁、至少一次初级保健就诊且2016年1月至2018年6月间FIT或mt-sDNA阳性的患者。
- 评估阳性后6个月内结肠镜完成情况,并查阅病历确定未行结肠镜的原因。
主要发现
- FIT阳性患者308例,mt-sDNA阳性患者323例。
- FIT阳性者46.7%在6个月内行结肠镜,mt-sDNA阳性者71.5%在6个月内行结肠镜。
- mt-sDNA阳性者结肠镜时间更短(风险比1.83;95%CI 1.48-2.25),多变量模型调整患者特征后差异仍存在。
- FIT后未行结肠镜者中,系统、提供者、患者相关障碍分别占32.1%、57.6%、36.3%。
- mt-sDNA后未行结肠镜者中,系统、提供者、患者相关障碍分别占30.4%、43.5%、57.6%。
临床怎么用
- 对FIT或mt-sDNA阳性患者应主动安排结肠镜随访,关注提供者与系统层面的障碍。
- 针对未随访者需识别并解决患者、提供者及系统多层面障碍。
局限性
- 研究为单中心学术健康系统回顾性分析,结果外推需谨慎。
- 未随访原因基于病历回顾,可能存在记录不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fecal immunochemical testing (FIT) and multi-target stool DNA testing (mt-sDNA) are recommended colorectal cancer screening options but require follow-up with colonoscopy to determine the source of a positive result. We performed a retrospective analysis in an academic health system to determine adherence to colonoscopy in these patients. METHODS: We identified all patients aged 40 years and older with at least 1 primary care visit who had a positive FIT or mt-sDNA between January 2016 and June 2018. We identified receipt of colonoscopy within 6 months of the positive test and reviewed medical records to determine reasons for lack of colonoscopy. RESULTS: We identified 308 eligible patients with positive FIT and 323 with positive mt-sDNA. Some patients with positive FIT (46.7%) and patients with positive mt-sDNA (71.5%) underwent colonoscopy within 6 months, and time to colonoscopy was also shorter with mt-sDNA (hazard ratio, 1.83; 95% CI, 1.48-2.25). These differences remained in a multivariable model adjusting for patient characteristics. Among patients without colonoscopy after positive FIT, 1 or more system, provider, and patient-related barriers were identified in 32.1%, 57.6%, and 36.3%, respectively. Among patients without colonoscopy after positive mt-sDNA, corresponding frequencies were 30.4%, 43.5%, and 57.6%, respectively. CONCLUSIONS: Follow-up colonoscopy was higher for mt-sDNA than FIT, which could be due in part to preselection by clinicians and/or patients. Among patients who did not follow-up, provider and system factors were as frequently encountered as patient factors. These findings reinforce the need for multi-level interventions to improve follow-up.
引用
- Cooper GS, Grimes A, Werner J, et al. Barriers to Follow-Up Colonoscopy After Positive FIT or Multitarget Stool DNA Testing. J Am Board Fam Med. 2021. PMID: 33452083. doi:10.3122/jabfm.2021.01.200345
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。